Afrezza is a great product! A painless, needless system for diabetic patients. Single use cartridge, in a reusable device. Although similar problems as all inhalants, the indicated use and manufacturing costs makes it a more favorable investment.
The more they sell, the more they lose. It is a nightmare scenario for anyone who would buy them. Would take millions to re-invest in the remanufacturing of the device towards a lower cost, and a new FDA submission. There are alternative technologies available for rapid drug delivery...unfortunately, no one has been successful in the aerosol drug delivery. Look at Allergan's acquisition of MAP, and they fact that 2 years later, they still do not have FDA approval.